Attention Health Care Professional:
Step 2. To dry, shake off excess water and let the mouthpiece air dry thoroughly, such
as overnight (see Figure B). When the mouth piece is dry, replace the canister and the
Detach Patient’s Instructions for Use from package
mouthpiece cap. Blockage from medi cation buildup is more likely to occur if the
insert and dispense with the product.
mouth piece is not allowed to air dry thoroughly.
6. IF YOUR INHALER HAS BECOME BLOCKED
(little or no medication coming out of the
mouthpiece, see Figure C), wash the mouthpiece as described in Step 1 and air drythoroughly as described in Step 2.
6. IF YOU NEED TO USE YOUR INHALER BEFORE IT IS COMPLETELY DRY, SHAKE OFF
replace the canister, and test spray twice into the air, away from your
face, to remove most of the water remaining in the mouthpiece. Then take your dose
FOR ORAL INHALATION ONLY
as prescribed. After such use, rewash and air dry thoroughly as described in Steps
1 and 2.
The correct amount of medication in each inhalation cannot be assured after 200
actuations, even though the canister is not completely empty. The canister should be
Instructions for Use
discarded when the labeled number of actuations have been used. Before you reachthe specific number of actuations, you should consult your physician to determinewhether a refill is needed. Just as you should not take extra doses without consulting
your physician, you also should not stop using PROVENTIL HFA Inhalation Aerosol
You may notice a slightly different taste or spray force than you are used to withPROVENTIL HFA Inhalation Aerosol, compared to other albuterol inhalation aerosolproducts.
Use only as directed by your physician.
The action of PROVENTIL® HFA Inhalation Aerosol should last up to 4 to 6 hours.
Before using your PROVENTIL® HFA (albuterol sulfate) Inhalation Aerosol, read complete
PROVENTIL HFA Inhalation Aerosol should not be used more frequently than
instructions carefully. Children should use PROVENTIL HFA Inhalation Aerosol under
recommended. Do not increase the number of puffs or frequency of doses of PROVENTIL
adult supervision, as instructed by the patient’s doctor.
HFA Inhalation Aerosol without consulting your physician. If you find that treat ment withPROVENTIL HFA Inhalation Aerosol becomes less effective for symptomatic relief, yoursymptoms become worse, and/or you need to use the product more frequently than
Please note that indicates that this inha lation aerosol does not contain
usual, medical attention should be sought immed iately. While you are taking PROVENTIL
chlorofluoro carbons (CFCs) as the propellant.
HFA Inhalation Aerosol, other inhaled drugs should be taken only as directed by your
SHAKE THE INHALER WELL immediately before each use. Then remove the cap from
physician. If you are pregnant or nursing, contact your phy sician about the use of
(see Figure 1). Check mouth piece for foreign objects prior to use.
Make sure the canister is fully inserted into the actuator.
Common adverse effects of treatment with PROVENTIL HFA Inhalation Aerosol include
As with all aerosol medications, it is recommended to prime the inhaler before using
palpitations, chest pain, rapid heart rate, tremor, or nervousness. Effective and safe use
for the first time and in cases where the inhaler has not been used for more than
of PROVENTIL HFA Inhalation Aerosol includes an understanding of the way that it
2 weeks. Prime by releasing four “test sprays” into the air, away from your face.
should be administered. Use PROVENTIL HFA Inhalation Aerosol only with the yellowactuator supplied with the product. The PROVENTIL HFA Inhalation Aerosol actuator
BREATHE OUT FULLY THROUGH THE MOUTH, expelling as much air from your lungs
should not be used with other aerosol medications.
as possible. Place the mouthpiece fully into the mouth, holding the inhaler in itsupright position (see Figure 2) and closing the lips around it.
For best results, use at room temperature. Avoid exposing product to extreme heat and cold.
WHILE BREATHING IN DEEPLY AND SLOWLY THROUGH THE MOUTH, FULLY
DEPRESS THE TOP OF THE METAL CANISTER with your index finger (see Figure 2).
Shake well before use.
HOLD YOUR BREATH AS LONG AS POSSIBLE, up to 10 seconds. Before breathing
Contents Under Pressure.
out, remove the inhaler from your mouth and release your finger from the canister.
Do not puncture. Do not store near heat or open flame. Exposure to temperatures above120°F may cause bursting. Never throw container into fire or incinerator. Store between
If your physician has prescribed additional puffs, wait 1 minute, shake the inhaler
15°-25°C (59°-77°F). Avoid spraying in eyes. Keep out of reach of children.
again, and repeat steps 3 through 5. Replace the cap after use.
Further Information: Your PROVENTIL® HFA (albuterol sulfate) Inhalation Aerosol does
KEEPING THE PLASTIC MOUTHPIECE CLEAN IS EXTREMELY IMPORTANT TO
not contain chlorofluorocarbons (CFCs) as the pro pellant. Instead, the inhaler contains a
PREVENT MEDICATION BUILDUP AND BLOCKAGE. THE MOUTHPIECE SHOULD BE
hydro-fluoro alkane (HFA-134a) as the propellant.
WASHED, SHAKEN TO REMOVE EXCESS WATER, AND AIR DRIED THOROUGHLY ATLEAST ONCE A WEEK. INHALER MAY STOP SPRAYING IF NOT PROPERLY CLEANED.
6. Routine cleaning instructions:
Step 1. To clean, remove the canister and mouth piece cap. Wash the mouthpiece
through the top and bottom with warm running water for 30 seconds at least once
a week (see Figure A). Never immerse the metal canister in water.
Developed and Manufactured by3M Health Care LimitedLoughborough UK
For: Schering Corporation, a subsidiary of Schering-Plough Corporation, Kenilworth, NJ 07033 USA.
1996, 1998, Schering Corporation. All rights reserved.
WWW.STEVECARR.CO.NZ Middens and Marshmallows: the magical world of Steve Carr A relative newcomer to the New Zealand art scene, Steve Carr is no stranger to Dunedin. Before obtaining his Masters degree from the Auckland University Elam School of Fine Arts in 2003, he graduated with a Bachelor of Fine Arts from the Otago Polytechnic. He also went on to co-found the now iconic Blue Oyster Ga
Menopausia y enfermedad cardiovascular: la evidencia Menopause and cardiovascular disease: the evidence Rosano G M, Vitale C, Marazzi G y Volterrani M Department of Medical Sciences, Center for Clinical and Basic Research, Cardiovascular Research Unit, El artículo original fue publicado en: Como terapia de reemplazo hormonal, la drospirenona en combinación con el 17β-estradiol